{'Year': '2013', 'Month': 'Jun'}
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.
Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and CYP2C8*3 genotype.